74 results on '"Buhl, Roland"'
Search Results
2. Response to biologics and clinical remission in the adult GAN severe asthma cohort.
3. German Asthma Net: Nasal polyposis in patients with severe asthma
4. Impact of smoking on biologicals treatment response in patients from the German Severe Asthma (GAN) Registry
5. Comparison of initial drug treatment of incident COPD patients with German treatment guidelines
6. CAPTAIN: Improvements in airflow obstruction in patients with uncontrolled asthma
7. Real-world treatment of incident COPD patients in Germany
8. CAPTAIN: Relationship between FEV1 reversibility at screening as a continuous variable and treatment response
9. Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort
10. Inhaled steroids and prevalence of osteoporosis in chronic obstructive pulmonary disease: Data from the DACCORD cohort
11. Small airway disease (SAD) is associated with respiratory symptoms and relevant for therapy in early COPD
12. Characterising individual response to mepolizumab treatment
13. The German Severe Asthma Registry: Obesity is associated with asthma parameters
14. Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma
15. The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history
16. Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma
17. Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
18. Smoking status and its impact on COPD: an analysis of the observational DACCORD study
19. The German Severe Asthma Registry and Type 2-high and Type 2-low asthma phenotypes
20. The frequent exacerbator in real-life: an analysis of the DACCORD study
21. COPD characteristics and progression of patients with high vs low health status: an analysis of the observational DACCORD study
22. Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
23. The German Severe Asthma Registry: FeNO values correlate with medical therapy, quality of life and smoking
24. Measurement of exhaled nitric oxide: comparison of 3 different analyzers
25. Effect of tiotropium/olodaterol combination therapy on long-term heart rate and blood pressure in COPD patients
26. Fractional exhaled nitric oxide is associated with more severe asthma
27. Disease control and treatment pathways of asthma patients after initiating ICS/LABA
28. COPD in elderly patients – an analysis of the DACCORD observational study
29. The Severe Asthma Registry – German data
30. Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma: a systematic review
31. Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study
32. Dual bronchodilation vs triple therapy in the real-life DACCORD study
33. Efficacy of once-daily tiotropium Respimat in adults with asthma based on GINA Steps 2–5
34. Low rate of exacerbations following initiation of LABA/LAMA fixed-dose combinations: An analysis of the DACCORD real life study
35. Determining SGRQ and TDI responder rates across the duration of clinical trials: Results from tiotropium + olodaterol in COPD
36. Effect of olodaterol once-daily on heart rate in GOLD 2–4 COPD patients
37. Late Breaking Abstract - Predictive value of FeNO in patients with non-specific respiratory symptoms: a randomised controlled trial
38. Clinically meaningful FEV1 response with reslizumab achieved early and sustained over 52 weeks
39. The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma
40. Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials
41. The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials
42. Combined tiotropium + olodaterol influences physical functioning in COPD: Results of an open-label observational study
43. 2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the 'real-life' DACCORD study
44. Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
45. Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema
46. Analysis of the frequency of COPD exacerbations in the 'real-life' DACCORD study over a 2 year period
47. Change of COPD maintenance medication over two years in a large real life cohort: The DACCORD study
48. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
49. Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
50. Cytomegalovirus (CMV) modulates the immune responses against inhaled harmless antigens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.